Retrospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 26, 2022; 10(24): 8547-8555
Published online Aug 26, 2022. doi: 10.12998/wjcc.v10.i24.8547
Clinical significance of half-hepatic blood flow occlusion technology in patients with hepatocellular carcinoma with cirrhosis
Dong Liu, Jian-Ming Fang, Xian-Qi Chen
Dong Liu, Department of General Surgery, Yongkang First People’s Hospital of Zhejiang Province, Yongkang 321300, Zhejiang Province, China
Jian-Ming Fang, Xian-Qi Chen, Department of Hepatopancreatobiliary Surgery, Jinhua Guangfu Oncology Hospital, Jinhua 321000, Zhejiang Province, China
Author contributions: Liu D and Chen XQ designed the research study; Liu D performed the research; Fang JM contributed new reagents and analytic tools; Liu D analyzed the data and wrote the manuscript; and all authors have read and approve the final manuscript.
Supported by Key Scientific Research Project of Jinhua Science and Technology Bureau in 2020 Fund, No. 2020-3-069.
Institutional review board statement: The study was reviewed and approved by the Yongkang First People’s Hospital of Zhejiang Province Institutional Review Board.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: Dr. Chen XQ reports grants from Scientific Research Project of Jinhua Science and Technology Bureau in 2020, during the conduct of the study. No other conflict of interest to declare.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xian-Qi Chen, BM BCh, Attending Doctor, Department of Hepatopancreatobiliary Surgery, Jinhua Guangfu Oncology Hospital, No. 1296 Huancheng North Road, Jinhua 321000, Zhejiang Province, China. cxqclz1988@163.com
Received: April 19, 2022
Peer-review started: April 19, 2022
First decision: May 11, 2022
Revised: May 23, 2022
Accepted: July 20, 2022
Article in press: July 20, 2022
Published online: August 26, 2022
Processing time: 118 Days and 14.7 Hours
ARTICLE HIGHLIGHTS
Research background

Hepatocellular carcinoma (HCC) accounts for 90% of all primary liver tumors.

Research motivation

Currently, radical surgery is the preferred treatment for HCC.

Research objectives

This study aimed to investigate the effect of half-hepatic blood flow occlusion after patients with HCC and cirrhosis undergo hepatectomy.

Research methods

This retrospective single-blinded study included 88 patients with HCC and liver cirrhosis who underwent hepatectomy from January 2017 to September 2020 in our hospital and were divided into an observation group and a control group.

Research results

About 24 h and 72 h after the operation the respective serum alanine transaminase and aspartate aminotransferase levels in the research group were significantly lower than those in the control group.

Research conclusions

Half-hepatic blood flow occlusion technology is more beneficial than total hepatic occlusion in reducing liver function injury in patients with HCC and cirrhosis undergoing hepatectomy.

Research perspectives

However, the sample size of this study was relatively small, and it is necessary to increase the sample size and detection indicators in future studies.